《细胞过继免疫治疗肿瘤的临床研究进展》由会员分享，可在线阅读，更多相关《细胞过继免疫治疗肿瘤的临床研究进展（67页珍藏版）》请在金锄头文库上搜索。
1、细胞过继免疫治疗肿瘤 的临床研究进展张叔人张叔人中国医学科学院中国医学科学院 北京协和医科大学北京协和医科大学肿瘤研究所肿瘤研究所细胞免疫治疗肿瘤的发展上世纪上世纪8080年代初，年代初，Steven Steven A. A. Rosenberg, Rosenberg, Chief of Surgery at the National Cancer Institute，NIHNIH，USUSLAK+IL-2 22LAK+IL-2 22例中：例中：CR1CR1，PR8PR8（41%41%）LAKLAK、TILTIL、基因修饰、基因修饰、联合放、化疗联合放、化疗国内细胞免疫治疗研究热潮uu 80
2、80年代末年代末9090年代初年代初LAKLAK推动了国内细胞免疫治疗推动了国内细胞免疫治疗研究的热潮。研究的热潮。LAKLAK：自体、异体、胎儿脾、胸腺、脐血：自体、异体、胎儿脾、胸腺、脐血 uu 9090年代，我国药品监督管理局制定了相应法规，并年代，我国药品监督管理局制定了相应法规，并公布实施。此后又进行了多次修订。公布实施。此后又进行了多次修订。首例申报首例申报CIKCIK，北京人民医院（陆道培），北京人民医院（陆道培）DCDC疫苗，第二军医大学（曹雪涛）疫苗，第二军医大学（曹雪涛） uu 上个世纪末上个世纪末CIKCIK、DC-CIKDC-CIK、NKNK、 gdgdT T、TIL
3、TIL 、免疫杀手细胞等开展了多种免疫细胞抗肿瘤研究。免疫杀手细胞等开展了多种免疫细胞抗肿瘤研究。肿瘤的细胞免疫治疗肿瘤的细胞免疫治疗经过体外培养加工经过体外培养加工uu 细胞细胞过继免疫治疗过继免疫治疗( (adoptive immunotherapy)adoptive immunotherapy)LAK LAK、TILTIL、CIKCIK、DC-CIKDC-CIK、NKNK、NKTNKT、CTL CTL 、 gdgdT T自体自体/ /异体，基因修饰异体，基因修饰uu 细胞细胞瘤苗瘤苗（tumor vaccinetumor vaccine）肿瘤细胞肿瘤细胞树突状细胞树突状细胞 自体自体/
4、/异体、基因修饰异体、基因修饰融合细胞融合细胞CIKCIK Cytokine induced killerCytokine induced killerPBMCIFN-g anti-CD3, IL-2, IL-1au2009，Germany，Prof. Dr. Schmidt-Wolf 建立了CIK临床研 究登记网站 www.cik-info.org，目前收集发表的文章39篇，中 国人发表26篇(占2/3)。u2011，J Cancer Res Clin Oncol. “Clinical trials on CIK cells: first report of the internationa
5、l registry on CIK cells (IRCC)”. PubMed the keywords CIK cells clinical trials，evaluated 11 studies（426人）. 并与作者联系核实u涉及的杂志：Digestive and Liver Disease, Chinese Journal of Cancer, Anticancer Research, World Journal of Gastroenterology , Haematologica, British Journal of Cancer, Biology of Blood, and M
6、arrow Transplantation. In some studies, abstracts were only available in Chinese.uUnfortunately, these studies are often published only in Chinese. international standard CIK 临床研究国际登记网站Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC)C. Hontscha Y. Borck H.
7、 Zhou D. Messmer I. G. H. Schmidt-WolfJ Cancer Res Clin Oncol (2011) 137:305310入组标准 排除标准Table 2. Indications and contraindications of CIK immunotherapy in 11 clinical trialsTable 1 Tumor entity with number of respective patients, male-to-female ratio, andtherapeutic effectsClinical trials on CIK cel
8、ls: first report of the international registry on CIK cells (IRCC)脊髓发育不良Cytokine Induced Killer Cells as Promising Immunotherapy for Solid Tumors Dario Sangiolo, Italy Journal of Cancer 2011; 2: 363-36 CIK治疗实体瘤的9个临床研究报道Fig. 1. Disease-free survival curves of the three groups. KaplanMeier was employe
9、d to estimate the disease-free survival rates of the three groups. Logrank test shows a significantly higher rates in the CIK-I group (p = 0.001) and the CIK-II group (p = 0.004) than in the control group. No statistical significance was found between the CIK-I group and the CIK-II group (p = 0.345)
10、.A randomized, controlled trial of postoperative adjuvant cytokine-induced killer cells immunotherapy after radical resection of hepatocellular carcinoma（127例）Hui Dong, Qiang Li , Jian Wang, Ti Zhang, Da-Lu Kong, Digestive and Liver Disease 41 (2009) 3641Department of Hepatobiliary Surgery, Cancer H
11、ospital of Tianjin Medical University, Tianjin, Peoples Republic of China无病生存期肝癌切除术后1个 月开始治疗，CIK-I x3次CIK-II x6次对照1 year3 years5 yearscontrol82.620.911.2CIK-I83.131.723.3CIK-II84.730.519.4Fig. 2 The 1-, 3- and 5-year disease-free survival rates in patients receiving CIK cells (groups 1 and 2) when c
12、ompared to no CIK cell treatment (127 patients); (trial 11). Group 1 was treated with 3 courses of CIK cells, group 2 was treated with 6 courses of CIK cells and the control group (group 3) received no CIK cell treatment for comparison1-, 3- 和 5-年无病生存率A randomized, controlled trial of postoperative
13、adjuvant cytokine-induced killer cells immunotherapy after radical resection of hepatocellular carcinoma（127例）A randomized, controlled trial of postoperative adjuvant cytokine-induced killer cells immunotherapy after radical resection of hepatocellular carcinoma1 year3 years5 yearscontrol87.165.236.
14、9CIK-I87.366.737.9CIK-II86.763.838.11-, 3- and 5-year overall survival rates生存期Figure 1 Survival rates of patients after cytokine-induced killer cells immunotherapy plus chemotherapy and chemotherapy alone. CIK: Cytokineinduced killer.CIK治疗胃癌频率与疗效Increasing the frequency of CIK cells adoptive immuno
15、therapy may decrease risk of death in gastric cancer patients (156例)Jing-Ting Jiang, . Xue-Guang Zhang 苏州大学World J Gastroenterol 2010 December 28; 16(48): 6155-6162World J Gastroenterol 2010 December 28; 16(48): 6155-6162Jing-Ting Jiang, Yue-Ping Shen, Chang-Ping Wu, Yi-Bei Zhu, Wen-Xiang Wei, Lu-Ju
16、n Chen, Xiao Zheng,Jing Sun, Bin-Feng Lu, Xue-Guang Zhang 苏州大学Increasing the frequency of CIK cells adoptive immunotherapy may decrease risk of death in gastric cancer patientsCord blood-derived cytokine-induced killer cells biotherapy combined with second-line chemotherapy in the treatment of advanced s
